Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs Mepolizumab (Primary) ; Omalizumab (Primary)
- Indications Allergic asthma; Eosinophilia
- Focus Therapeutic Use
- Acronyms PREDICTUMAB
- 12 Jul 2019 Status changed from not yet recruiting to recruiting.
- 08 Apr 2019 Planned initiation date changed from 30 Mar 2018 to 1 May 2018.
- 31 Aug 2018 Biomarkers information updated